While there is strong evidence that PPARα is required to mediate liver carcinogenesis caused by chronic ligand activation of PPARα in rodents, there is equally convincing evidence that humans do not develop liver cancer following administration of PPARα agonists (reviewed in [5,9,10,11,21,22,49,50]). The gene discussed is PPARA; the disease is liver cancer.